Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 Deficiency
July 21, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, July 21, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human Resources
July 13, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 Deficiency
June 09, 2021 07:30 ET
|
Inozyme Pharma Inc.
- Clinical trial initiation expected in mid-2021 –- Preliminary safety and biomarker data expected by the end of 2021 - BOSTON, June 09, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq:...
Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business Highlights
May 12, 2021 06:00 ET
|
Inozyme Pharma Inc.
– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 – – Published peer-reviewed preclinical data supporting...
Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency
May 07, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization,...
Inozyme Pharma to Present at the BofA Securities 2021 Virtual Healthcare Conference
May 06, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced...
Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 Deficiency
April 29, 2021 07:30 ET
|
Inozyme Pharma Inc.
- Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse...
Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical Conferences
April 28, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization...
Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
April 14, 2021 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today...